Targeting histone deacetylases in pancreatic ductal adenocarcinoma.

Journal of Cellular and Molecular Medicine
Günter SchneiderDieter Saur

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a median survival below 6 months and a 5-year survival rate below 1%. Effective therapies for locally advanced or metastatic tumours are missing and curatively resected patients relapse in over 80% of the cases. Although histone deacetylases (HDACs) are involved in the control of proliferation, apoptosis, differentiation, migration and angiogenesis of cancer cells, knowledge about the expression patterns and functions of individual HDAC isoenzymes in pancreatic cancer is sparse. This review summarizes the roles of HDACs as novel therapeutic targets and the molecular mode of action of HDAC-inhibitors (HDACI) in PDACs. Success of HDACI in clinical settings will depend on an increased knowledge of HDAC functions as well as on a better understanding of the mode of action of HDACI. Pre-clinical experimental data that constitute the basis for rational therapeutic strategies to treat PDAC are described here. Translating these rational-based therapies into the clinic will finally increase our chance to establish an effective HDACI-containing combination therapy effective against PDAC.

References

Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·A SaitoO Nakanishi
Aug 7, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jung-Hyun ParkYung-Jue Bang
May 12, 2005·Gastroenterology·Günter SchneiderRoland M Schmid
Aug 12, 2005·Molecular Cancer Therapeutics·Pilar García-MoralesMiguel Saceda
Aug 20, 2005·Biochimica Et Biophysica Acta·Federica NatoniMaria Saveria Gilardini Montani
Feb 24, 2006·Nature Reviews. Molecular Cell Biology·Jean Paul Thiery, Jonathan P Sleeman
Mar 29, 2006·Virchows Archiv : an International Journal of Pathology·Paolo PiacentiniAldo Scarpa
Aug 15, 2006·Biochemical and Biophysical Research Communications·Jirong BaiMark P Callery
Sep 7, 2006·Nature Reviews. Drug Discovery·Jessica E BoldenRicky W Johnstone
Oct 17, 2006·Expert Opinion on Investigational Drugs·Florian EckelRoland M Schmid
Jan 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nichole Boyer ArnoldMurray Korc
Apr 10, 2007·International Journal of Cancer. Journal International Du Cancer·Takashi KumagaiH Phillip Koeffler
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela MünsterAdil Daud
Jun 9, 2007·Biochimica Et Biophysica Acta·Massimo DonadelliMarta Palmieri
Aug 19, 2007·Oncogene·M A Glozak, E Seto
Feb 23, 2008·Nature Reviews. Molecular Cell Biology·Xiang-Jiao Yang, Edward Seto
Mar 14, 2008·Current Cancer Drug Targets·Simone Fulda
Jul 3, 2008·World Journal of Gastroenterology : WJG·Martin HaefnerMarcus Wiedmann
Jul 26, 2008·Molecular Cancer·Rainer HamacherGünter Schneider
Sep 6, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hubert KasperczykSimone Fulda
Sep 23, 2008·The International Journal of Biochemistry & Cell Biology·Stephanie SpangeOliver H Krämer
Oct 1, 2008·Cancer Letters·Olaf WittIna Oehme
Dec 24, 2008·Cancer Letters·Wilko Weichert
Mar 18, 2009·Cancer Letters·Sriram BalasubramanianJoseph J Buggy
Apr 4, 2009·Cancer Letters·Marc BuchwaldThorsten Heinzel
Apr 11, 2009·Cancer Letters·Ailsa J FrewJessica E Bolden
May 22, 2009·Journal of Cellular Biochemistry·P A Marks, W-S Xu

❮ Previous
Next ❯

Citations

Jan 29, 2011·Journal of Gastrointestinal Cancer·Günter SchneiderDieter Saur
Oct 18, 2012·Cancer Letters·Angela L McCleary-WheelerMartin E Fernandez-Zapico
Nov 17, 2010·Cancer Letters·Alexander ArltHeiner Schäfer
Oct 19, 2013·Biochemical and Biophysical Research Communications·Akihiro YamamuraAkira Horii
Apr 20, 2010·Molecular Cancer·Susanne SchülerGünter Schneider
Sep 27, 2016·Expert Opinion on Investigational Drugs·Alexander Arlt, Heiner Schäfer
Aug 26, 2014·World Journal of Gastroenterology : WJG·Shing-Chun Tang, Yang-Chao Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.